RCT: Aumolertinib vs. Gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations.
26 May, 2022 | 10:10h | UTC
Commentary on Twitter
Aumolertinib (a 3rd gen TKI) is effective in the first-line treatment of EGFR-mutant NSCLC-AENEAShttps://t.co/QL6xXptxFa pic.twitter.com/grIbapsxzU
— K Pavithran (@drkpavithran) May 18, 2022
https://creativecommons.org/licenses/by-nc-nd/4.0/